To the Editor Recently, with the increasing research on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs), recurrence of irAEs after ICI rechallenge has deserved more attention. In their cohort study, Dolladille and colleagues1 retrospectively assessed safety in patients with cancer who resumed therapy with the same ICIs and found that ICI rechallenge was associated with a recurrence of the same irAEs in one-quarter to one-third of the cases. However, there are some suggestions of this study that ought to be carefully considered, especially considering its promising research future as to ICIs.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Zheng S, Duan H, Cui H. Recurrence of Immune-Related Adverse Events After Immune Checkpoint Inhibitor Rechallenge. JAMA Oncol. 2020;6(11):1813. doi:10.1001/jamaoncol.2020.3946
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: